Guangwei Li1, Ping Zhang2, Jinping Wang3, Yali An4, Qiuhong Gong4, Edward W Gregg5, Wenying Yang6, Bo Zhang6, Ying Shuai6, Jing Hong6, Michael M Engelgau7, Hui Li3, Gojka Roglic8, Yinghua Hu3, Peter H Bennett9. 1. Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China; Center of Endocrinology and Cardiovascular Disease, National Center of Cardiology & Fuwai Hospital, Beijing, China. Electronic address: guangwei_li@medmail.com.cn. 2. Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: pzhang@cdc.gov. 3. Department of Cardiology, Da Qing First Hospital, Da Qing, China. 4. Center of Endocrinology and Cardiovascular Disease, National Center of Cardiology & Fuwai Hospital, Beijing, China. 5. Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6. Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China. 7. Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA. 8. Department of Management of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland. 9. Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA.
Abstract
BACKGROUND: Lifestyle interventions among people with impaired glucose tolerance reduce the incidence of diabetes, but their effect on all-cause and cardiovascular disease mortality is unclear. We assessed the long-term effect of lifestyle intervention on long-term outcomes among adults with impaired glucose tolerance who participated in the Da Qing Diabetes Prevention Study. METHODS: The study was a cluster randomised trial in which 33 clinics in Da Qing, China-serving 577 adults with impaired glucose tolerance-were randomised (1:1:1:1) to a control group or lifestyle intervention groups (diet or exercise or both). Patients were enrolled in 1986 and the intervention phase lasted for 6 years. In 2009, we followed up participants to assess the primary outcomes of cardiovascular mortality, all-cause mortality, and incidence of diabetes in the intention-to-treat population. FINDINGS: Of the 577 patients, 439 were assigned to the intervention group and 138 were assigned to the control group (one refused baseline examination). 542 (94%) of 576 participants had complete data for mortality and 568 (99%) contributed data to the analysis. 174 participants died during the 23 years of follow-up (121 in the intervention group vs 53 in the control group). Cumulative incidence of cardiovascular disease mortality was 11.9% (95% CI 8.8-15.0) in the intervention group versus 19.6% (12.9-26.3) in the control group (hazard ratio [HR] 0.59, 95% CI 0.36-0.96; p=0.033). All-cause mortality was 28.1% (95% CI 23.9-32.4) versus 38.4% (30.3-46.5; HR 0.71, 95% CI 0.51-0.99; p=0.049). Incidence of diabetes was 72.6% (68.4-76.8) versus 89.9% (84.9-94.9; HR 0.55, 95% CI 0.40-0.76; p=0.001). INTERPRETATION: A 6-year lifestyle intervention programme for Chinese people with impaired glucose tolerance can reduce incidence of cardiovascular and all-cause mortality and diabetes. These findings emphasise the long-term clinical benefits of lifestyle intervention for patients with impaired glucose tolerance and provide further justification for adoption of lifestyle interventions as public health measures to control the consequences of diabetes. FUNDING: Centers for Disease Control and Prevention, WHO, the China-Japan Friendship Hospital, Da Qing First Hospital.
BACKGROUND: Lifestyle interventions among people with impaired glucose tolerance reduce the incidence of diabetes, but their effect on all-cause and cardiovascular disease mortality is unclear. We assessed the long-term effect of lifestyle intervention on long-term outcomes among adults with impaired glucose tolerance who participated in the Da Qing Diabetes Prevention Study. METHODS: The study was a cluster randomised trial in which 33 clinics in Da Qing, China-serving 577 adults with impaired glucose tolerance-were randomised (1:1:1:1) to a control group or lifestyle intervention groups (diet or exercise or both). Patients were enrolled in 1986 and the intervention phase lasted for 6 years. In 2009, we followed up participants to assess the primary outcomes of cardiovascular mortality, all-cause mortality, and incidence of diabetes in the intention-to-treat population. FINDINGS: Of the 577 patients, 439 were assigned to the intervention group and 138 were assigned to the control group (one refused baseline examination). 542 (94%) of 576 participants had complete data for mortality and 568 (99%) contributed data to the analysis. 174 participants died during the 23 years of follow-up (121 in the intervention group vs 53 in the control group). Cumulative incidence of cardiovascular disease mortality was 11.9% (95% CI 8.8-15.0) in the intervention group versus 19.6% (12.9-26.3) in the control group (hazard ratio [HR] 0.59, 95% CI 0.36-0.96; p=0.033). All-cause mortality was 28.1% (95% CI 23.9-32.4) versus 38.4% (30.3-46.5; HR 0.71, 95% CI 0.51-0.99; p=0.049). Incidence of diabetes was 72.6% (68.4-76.8) versus 89.9% (84.9-94.9; HR 0.55, 95% CI 0.40-0.76; p=0.001). INTERPRETATION: A 6-year lifestyle intervention programme for Chinese people with impaired glucose tolerance can reduce incidence of cardiovascular and all-cause mortality and diabetes. These findings emphasise the long-term clinical benefits of lifestyle intervention for patients with impaired glucose tolerance and provide further justification for adoption of lifestyle interventions as public health measures to control the consequences of diabetes. FUNDING: Centers for Disease Control and Prevention, WHO, the China-Japan Friendship Hospital, Da Qing First Hospital.
Authors: Anne E Sumner; Michelle T Duong; Paola C Aldana; Madia Ricks; Marshall K Tulloch-Reid; Jay N Lozier; Stephanie T Chung; David B Sacks Journal: Diabetes Care Date: 2015-12-17 Impact factor: 19.112
Authors: Elizabeth C Rhodes; Eeshwar K Chandrasekar; Shivani A Patel; K M Venkat Narayan; Thomas V Joshua; Lovoria B Williams; Lucy Marion; Mohammed K Ali Journal: Diabetes Res Clin Pract Date: 2018-09-28 Impact factor: 5.602
Authors: Matthew J O'Brien; Margaret R Moran; Joyce W Tang; Maria C Vargas; Mary Talen; Laura J Zimmermann; Ronald T Ackermann; Namratha R Kandula Journal: Diabetes Educ Date: 2016-09-12 Impact factor: 2.140